AzTrials
AzTrials

Colorectal NeoplasmsCOMET-OPTICALNCT05349110

Real-time Diagnosis of Diminutive Colorectal Polyps Using AI

An observational study of Colorectal Neoplasms and Colorectal Polyp, run by Maastricht University Medical Center at 2 sites in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Correct endoscopic prediction of the histopathology and differentiation between benign, pre-malignant, and malignant colorectal polyps (optical diagnosis) remains difficult. Artificial intelligence has great potential in image analysis in gastrointestinal endoscopy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Colorectal Neoplasms, Colorectal Polyp
What is being tested?
Computer-aided diagnosis (CADx) systems
Type of treatment
Medical device
How many people
105 participants
Where
2 sitesNetherlands
Study dates
20 Aug 2021to Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.

Who may be able to join

  • Age >18 years;
  • Patients with at least one colorectal polyps encountered during colonoscopy;
  • Patients referred for a colonoscopy by the Dutch bowel cancer screening program, patients undergoing a colonoscopy for endoscopic surveillance, or patients undergoing a colonoscopy because of complaints;
  • Written informed consent.

Who cannot join

  • Patients with prior history of inflammatory bowel diseases (IBD) or polyposis syndromes;
  • Patients with inadequate bowel preparations after adequate washing, suctioning, and cleaning manoeuvres have been performed by the endoscopist;
  • Patients undergoing an emergency colonoscopy;
  • Written objection in the patient file for participation in scientific research.

Trial locations and contacts

2 sites in 1 country.

Quirine van der Zander, Drs MD contact

031433882241

q.vanderzander@maastrichtuniversity.nl

Erik Schoon, Prof Dr MD contact

031433882241

erik.schoon@catharinaziekenhuis.nl

Netherlands2 sites, 1 recruiting
  • Catharina Ziekenhuis Eindhoven

    Eindhoven, North Brabant, 5623 EJ

    Completed
  • Maastricht University Medical Center

    Maastricht, Limburg, 6202AZ

    Quirine van der Zander, Drs MD, 031433882241, q.vanderzander@maastrichtuniversity.nl

    Erik Schoon, Prof Dr MD, 031433882241, erik.schoon@catharinaziekenhuis.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Real Time Computer-aided Diagnosis (CADx) of Diminutive Colorectal Polyps Using Artificial Intelligence

Correct endoscopic prediction of the histopathology and differentiation between benign, pre-malignant, and malignant colorectal polyps (optical diagnosis) remains difficult. Artificial intelligence has great potential in image analysis in gastrointestinal endoscopy. Aim of this study is to investigate the real-time diagnostic performance of AI4CRP for the classification of diminutive colorectal polyps, and to compare it with the real-time diagnostic performance of commercially available CADx systems.

Read the detailed description

Correct endoscopic prediction of the histopathology and differentiation between benign, pre-malignant, and malignant colorectal polyps (optical diagnosis) remains difficult. Despite additional training, even experienced endoscopists continue to fail meeting international thresholds set for safe implementation of treatment strategies based on optical diagnosis.

Multiple machine learning techniques - computer-aided diagnosis (CADx) systems - have been developed for applications in medical imaging within colonoscopy and can improve endoscopic classification of colorectal polyps.

Aim of this study is to explore the feasibility of the workflow using AI4CRP (a CNN based CADx system) real-time in the endoscopy suite, and to investigate the real-time diagnostic performance of AI4CRP for the diagnosis of diminutive (<5mm) colorectal polyps. Secondary, the real-time performance of commercially available CADx systems will be investigated and compared with AI4CRP performance.

Being tested
Computer-aided diagnosis (CADx) systems
Keywords
Artificial intelligence, Computer-aided diagnosis (CADx)
Medical subject headings
Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Computer-aided diagnosis (CADx) systemsDevice

    Also called AI4CRP, artificial intelligence for colorectal polyps (COMET-OPTICAL research group), CAD EYE (Fujifilm® Corporation, Tokyo, Japan)

    • AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);
    • CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan).
Study groups in NCT05349110
Study groupRoleWhat they receive
Gastroenterology patientsPatient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases. Colonoscopies will be executed using Fujifilm endoscopy systems (Fujifilm® Corporation, Tokyo, Japan), using Pentax endoscopy systems (Pentax Medical®, Hamburg, Germany), and using Olympus endoscopy systems (Olympus®, Tokyo, Japan).
Receives: Device: Computer-aided diagnosis (CADx) systems

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical feasibility of real-time use of AI4CRP.

    The technical feasibility of real-time use of AI4CRP in the endoscopy suite regarding a proper reception of the video output from the local endoscopy processor towards AI4CRP (in high definition quality, without any delays in time).

    Measured: 6 months

  2. User interface feasibility of real-time use of AI4CRP.

    The user interface feasibility of real-time use of AI4CRP in the endoscopy suite regarding a correct alignment of the user interface of AI4CRP with the video output from the local endoscopy system (resizing image pixels and anonymization).

    Measured: 6 months

  3. The diagnostic accuracy of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time diagnostic accuracy of AI4CRP per image modality (HDWL, BLI, LCI, i-scan). Diagnostic accuracy defined as the percentage of correctly optically diagnosed colorectal polyps.

    Measured: 1 year

  4. The sensitivity of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time sensitivity of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    Measured: 1 year

  5. The specificity of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time specificity of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    Measured: 1 year

  6. The negative predictive value of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time negative predictive value of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    Measured: 1 year

  7. The positive predictive value of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time positive predictive value of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    Measured: 1 year

  8. The Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    The real-time Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).

    Measured: 1 year

Secondary outcomes (21)
  1. The diagnostic accuracy of AI4CRP per polyp.

    The real-time diagnostic accuracy of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  2. The sensitivity of AI4CRP per polyp.

    The real-time sensitivity of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  3. The specificity of AI4CRP per polyp.

    The real-time specificity of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  4. The negative predictive value of AI4CRP per polyp.

    The real-time negative predictive value of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  5. The positive predictive value of AI4CRP per polyp.

    The real-time positive predictive value of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  6. The Area Under ROC Curve (AUC) of AI4CRP per polyp.

    The real-time Area Under ROC Curve (AUC) of AI4CRP per polyp (comprising the combination of different imaging modalities).

    Measured: 1 year

  7. The diagnostic accuracy of CAD EYE in BLI mode, per polyp.

    The real-time diagnostic accuracy of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  8. The sensitivity of CAD EYE in BLI mode, per polyp.

    The real-time sensitivity of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  9. The specificity of CAD EYE in BLI mode, per polyp.

    The real-time specificity of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  10. The negative predictive value of CAD EYE in BLI mode, per polyp.

    The real-time negative predictive value of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  11. The positive predictive value of CAD EYE in BLI mode, per polyp.

    The real-time positive predictive value of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  12. The Area Under ROC Curve (AUC) of CAD EYE in BLI mode, per polyp.

    The real-time Area Under ROC Curve (AUC) of CAD EYE in BLI mode, per polyp.

    Measured: 1 year

  13. The diagnostic accuracy of AI4CRP per patient.

    The real-time diagnostic accuracy of AI4CRP per patient (in case of multiple polyps per patient).

    Measured: 1 year

  14. The diagnostic accuracy of CAD EYE per patient.

    The real-time diagnostic accuracy of CAD EYE per patient (in case of multiple polyps per patient).

    Measured: 1 year

  15. The localization score of AI4CRP.

    The localization score of AI4CRP regarding the number of images in which the heatmap produced by AI4CRP pointed out the area of interest (scale: correct, incorrect, or partly correct area of interest).

    Measured: 1 year

  16. The difference in diagnostic accuracy of endoscopists per polyp before and after AI.

    The difference in real-time diagnostic accuracy of endoscopists per polyp before and after AI.

    Measured: 1 year

  17. The difference in sensitivity of endoscopists per polyp before and after AI.

    The difference in real-time sensitivity of endoscopists per polyp before and after AI.

    Measured: 1 year

  18. The difference in specificity of endoscopists per polyp before and after AI.

    The difference in real-time specificity of endoscopists per polyp before and after AI.

    Measured: 1 year

  19. The difference in negative predictive value of endoscopists per polyp before and after AI.

    The difference in real-time negative predictive value of endoscopists per polyp before and after AI.

    Measured: 1 year

  20. The difference in positive predictive value of endoscopists per polyp before and after AI.

    The difference in real-time positive predictive value of endoscopists per polyp before and after AI.

    Measured: 1 year

  21. The agreement in surveillance interval based on optical diagnosis and histopathology.

    The agreement in surveillance interval based on optical diagnosis of diminutive colorectal polyps and histopathology of small and large colorectal polyps, compared to the surveillance interval based on histopathology of all colorectal polyps (diminutive, small, and large).

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2022
  2. Study start20 Aug 2021
  3. Primary completionSep 2022 (estimated)
  4. Study completionDec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
105 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05349110
Sponsor's protocol ID
METC2021-3036
Acronym
COMET-OPTICAL
Status last verified
Apr 2022
First submitted
31 Mar 2022
Last updated
5 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: A data sharing plan is not yet decided on.

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Neoplasms and Colorectal Polyp, run by Maastricht University Medical Center at 2 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Quirine van der Zander, Drs MD (031433882241, q.vanderzander@maastrichtuniversity.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical feasibility of real-time use of AI4CRP. (time frame: 6 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in